GlassScriptPhysician profile
Amber Jo Stocco
NPI 1992930838
$4,426.85
in general payments reported to CMS, 2019-2025
35 companies · $15.42 in 2025
The $15.42 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,218 · 2020: $496 · 2021: $1,283 · 2022: $1,166 · 2023: $248 · 2025: $15.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $263.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,174.20 | 2021-2022 | |
| Ucb, INC. | $519.26 | 2019-2023 | Fintepla |
| Livanova USA, INC. | $471.07 | 2019-2022 | |
| Eisai INC. | $413.86 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $325.95 | 2019-2021 | |
| Greenwich Biosciences, INC. | $221.64 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $133.56 | 2022-2023 | Epidiolex |
| Amneal Pharmaceuticals LLC | $121.31 | 2019-2021 | |
| Medtronic USA, INC. | $120.10 | 2019 | |
| Neurelis, INC. | $114.57 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $104.32 | 2019 | |
| Xeris Pharmaceuticals, INC. | $90.36 | 2022-2023 | Gvoke Hypopen |
| Immedica Pharma US, INC. | $82.47 | 2022-2023 | |
| Aquestive Therapeutics, INC. | $68.63 | 2020-2022 | |
| Tris Pharma INC | $41.00 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ptc Therapeutics, INC. | $40.99 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $40.80 | 2019-2022 | |
| Biogen, INC. | $35.05 | 2019-2020 | |
| Rhodes Pharmaceuticals L.P. | $33.22 | 2019 | |
| Mallinckrodt Enterprises LLC | $31.35 | 2019 | |
| Biomarin Pharmaceutical INC. | $22.65 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.90 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $18.95 | 2022 | |
| Shire North American Group INC | $18.33 | 2019 | |
| Genzyme Corporation | $17.32 | 2021 | |
| Vanda Pharmaceuticals INC. | $16.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.82 | 2019 | |
| Ns Pharma, INC. | $15.72 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.71 | 2021 | |
| Pfizer INC. | $15.42 | 2025 | |
| Abbott Laboratories | $14.93 | 2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $14.91 | 2023 | Baqsimi |
| Lundbeck LLC | $13.22 | 2019 | |
| Upsher-Smith Laboratories LLC | $12.57 | 2021 | |
| Travere Therapeutics, INC. | $9.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Stocco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.